Pancreatic cancer, a notoriously elusive and deadly disease, has long resisted even the most advanced immunotherapies. But a groundbreaking discovery by Northwestern Medicine scientists offers a glimmer of hope. The secret to pancreatic cancer's resilience lies in its ability to disguise itself with a sugar-based cloak, evading the immune system's detection.
In a remarkable six-year journey, the research team not only unraveled this novel mechanism but also developed an antibody therapy to counter it. Associate Professor Mohamed Abdel-Mohsen, a key figure in this study, explains, "It was a major breakthrough to see our antibodies reawaken immune cells, turning them into cancer-attacking warriors."
This breakthrough, set to be published in the journal Cancer Research, marks the beginning of Pancreatic Cancer Awareness Month and a potential turning point in cancer treatment.
Pancreatic Cancer's Immune Evasion: Unveiling the Mystery
Pancreatic cancer is a formidable adversary, often diagnosed late with limited treatment options and a stark five-year survival rate of just 13%. It's known for its resistance to immunotherapies, leaving scientists puzzled.
Abdel-Mohsen and his team set out to understand why pancreatic tumors suppress the immune system's response. They aimed to flip this environment, empowering immune cells to attack tumor cells instead of ignoring or even aiding them.
The Sugar-Coated Tumor: A Wolf in Sheep's Clothing
The team's discovery was intriguing: pancreatic tumors exploit a natural safety system used by healthy cells. Healthy cells express a sugar called sialic acid on their surface, signaling to the immune system, "Don't harm me."
However, pancreatic tumors hijack this system by loading the same sugar onto a surface protein called integrin α3β1. This sugar coat allows the protein to bind to a sensor on immune cells called Siglec-10, sending a false "stand down" signal. In essence, the tumor sugar-coats itself, a clever disguise that allows it to escape immune surveillance.
A Novel Antibody: Unmasking the Tumor
Once the hiding mechanism was uncovered, the Northwestern scientists developed monoclonal antibodies to block it. When tested in the lab and animal models, these antibodies awakened immune cells, prompting them to devour cancer cells. Treated mice showed significantly slower tumor growth compared to untreated controls.
Developing these antibodies was a significant feat. Abdel-Mohsen explains, "We screened thousands of hybridomas, cells that produce antibodies, before finding the right one."
The Future of Treatment: Combination Therapy and Beyond
The next step, according to Abdel-Mohsen, is to combine this antibody with current chemotherapy and immunotherapy treatments. He believes there's a strong scientific basis for this approach, aiming for a full remission rather than just slowing tumor growth.
The team is now fine-tuning the antibody for human use, conducting early safety and dosing studies, and testing it in combination with other therapies. They're also developing a companion test to identify patients whose tumors rely on this sugar-based pathway, ensuring the right patients receive the right therapy.
Abdel-Mohsen estimates that, with continued progress, this therapy could be available to patients within five years.
Broader Implications: A New Frontier in Cancer Research
Beyond pancreatic cancer, this discovery could have far-reaching implications. Abdel-Mohsen's team is now investigating whether this sugar-coat trick is present in other hard-to-treat cancers like glioblastoma and in non-cancer diseases where the immune system is misled.
His lab's focus on glyco-immunology, the study of how sugars regulate the immune system, is a growing field with immense potential. "We're just beginning to explore this field," he says. "Here at Northwestern, we aim to translate these sugar-based insights into real treatments for cancer, infectious diseases, and aging-related conditions."
Abdel-Mohsen is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, leading the charge in this innovative research.
